More than 800 jobs will be created by Eli Lilly as part of a new €400m investment into Ireland as part of its global expansion.
As the Irish Examiner reports, the pharmaceutical giant has announced that the funding will be put into building a new facility in Co Limerick.
If it secures planning approval, the facility will need 500 people in the construction phase, and will employ 300 pharma workers when finished.
Planning for the site, at Raheen Business Park near Shannon Airport and just under 5km from Limerick City centre, is due to be submitted in the coming weeks.
The new facility will expand the company’s manufacturing network for biologic active ingredients, support increased demand for its existing products, and play a key role in bringing Lilly’s clinical pipeline — including its Alzheimer’s portfolio — to patients around the world.
The proposed project is expected to create new jobs for skilled engineers, scientists, and operations personnel who, the company says, will use the latest biologics manufacturing technology to produce “lifechanging treatments that patients need to address health challenges”.
Eli Lilly has been operating in Ireland since 1978 and currently has more than 2,500 employees at a manufacturing campus at Kinsale, a global business services centre at Little Island in Co Cork, and a commercial team dispersed across the country.
Biopharma hub
Tánaiste and Enterprise Minister Leo Varadkar said: “This is fantastic news for Limerick, and indeed the entire region.
The Mid-West has become a real hub for leading biopharma companies such as Lilly, and I’m really pleased the company has chosen Limerick for its new manufacturing centre.”
Senior vice president and president of manufacturing operations Edgardo Hernandez said: “Over the past 40 years, we have continued to invest in Ireland in part because of supportive government policies that value life science innovation.
"This new Lilly campus in Limerick will allow us to expand our capacity to make innovative new medicines that can help treat some of the world’s most serious illnesses.
This facility will use the latest technology to support advancements in science, productivity, and sustainability, further establishing Lilly as a global manufacturing leader.”
IDA Ireland chief executive Martin Shanahan said the investment is “very welcome news” for the Mid-West region.
“The decision to significantly expand its footprint into the region demonstrates the confidence Lilly has in Ireland and the region’s strong talent pool," he said.
